Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$314 Mln
Revenue (TTM)
$85 Mln
Net Profit (TTM)
$0 Mln
ROE
0 %
ROCE
-- %
P/E Ratio
127
P/B Ratio
2.8
Industry P/E
--
EV/EBITDA
223
Div. Yield
0 %
Debt to Equity
0
Book Value
$3.1
EPS
$0.1
Face value
--
Shares outstanding
34,746,187
CFO
$-201.68 Mln
EBITDA
$-232.89 Mln
Net Profit
$-266.11 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Delcath Systems (DCTH)
| -4.7 | 8.2 | -4.7 | -23.4 | 18.8 | -4.7 | -68.5 |
|
BSE Sensex
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Delcath Systems (DCTH)
| -16.1 | 186.9 | 15.6 | -53.5 | -56.8 | -15.7 | -89.2 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Delcath Systems (DCTH)
|
9.6 | 313.9 | 85.2 | 2.7 | 2.7 | 3 | 127 | 2.8 |
| 7.9 | 5,388.2 | 6,552.2 | -530.2 | -4.1 | -9.2 | -- | 0.9 | |
| 278.3 | 7,510.1 | 2,554.2 | 319.2 | 19.5 | 4.7 | 10 | 1.0 | |
| 36.8 | 5,222.6 | 3,436.5 | -8.6 | 2.2 | -0.4 | -- | 2.1 | |
| 112.8 | 6,549.6 | 507.4 | -187.7 | -36.2 | -26.4 | -- | 10.0 | |
| 76.1 | 4,758.4 | 1,541.6 | 233.6 | 21.6 | 21.4 | 21.4 | 4.5 | |
| 178.6 | 9,411.8 | 1,526.9 | -151.5 | 20.0 | -17.1 | -- | 12.9 | |
| 330.4 | 12,964.3 | 1,403.7 | 177.7 | 14.7 | 13.8 | 72.9 | 9.0 | |
| 117.8 | 6,280.4 | 738.3 | 48.9 | 11.4 | 2.4 | 129.6 | 3.0 | |
| 32.1 | 13,716.9 | 6,178.4 | 626.5 | 13.0 | 11.9 | 22.5 | 2.6 |
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic... delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. The company also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. The company was founded in 1988 and is headquartered in Queensbury, New York. Address: 566 Queensbury Avenue, Queensbury, NY, United States, 12804 Read more
CEO & Director
Mr. Gerard J. Michel MBA, MS
CEO & Director
Mr. Gerard J. Michel MBA, MS
Headquarters
Queensbury, NY
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Delcath Systems Inc (DCTH) is $9.63 (NASDAQ) as of 02-Apr-2026 16:00 EDT. Delcath Systems Inc (DCTH) has given a return of 18.76% in the last 3 years.
The P/E ratio of Delcath Systems Inc (DCTH) is 127.00 times as on 31-Mar-2026.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
136.33
|
3.31
|
|
2024
|
-14.61
|
5.61
|
|
2023
|
-2.01
|
6.09
|
|
2022
|
-0.97
|
-6.07
|
|
2021
|
-2.36
|
5.06
|
The 52-week high and low of Delcath Systems Inc (DCTH) are Rs 18.23 and Rs 8.12 as of 04-Apr-2026.
Delcath Systems Inc (DCTH) has a market capitalisation of $ 314 Mln as on 31-Mar-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Delcath Systems Inc (DCTH), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
$0.09
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.